Current Report Filing (8-k)
December 17 2018 - 8:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
December 15, 2018
CANCER
GENETICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
001-35817
|
|
04-3462475
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
201
Route 17 North 2nd Floor, Rutherford, New Jersey 07070
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code
(201) 528-9200
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
1.02 Termination of a Material Definitive Agreement.
Termination
of Merger Agreement
On
December 15, 2018, the Agreement and Plan of Merger (the “Merger Agreement”), dated September 18, 2018, among
Cancer Genetics, Inc. (“CGI” or the “Company”), a Delaware corporation, Wogolos Ltd., a company formed
under the laws of the State of Israel and a wholly-owned subsidiary of the Company (“Merger Sub”), and NovellusDx
Ltd., a privately-held company formed under the laws of the State of Israel (“NDX”), was terminated by the Company.
Descriptions
of the terms of the Merger Agreement were included in Item 1.01 of the Current Report on Form 8-K filed by the Company on September
21, 2018, and to the extent required by Item 1.02 of Form 8-K, such descriptions are incorporated by reference in this Item 1.02
pursuant to General Instruction B.3 of Form 8-K.
Termination
of Private Placement
As
a result of the termination of the Merger Agreement, the securities purchase agreement (the “Purchase Agreement”),
dated September 18, 2018, among the Company and certain investors party thereto, all of whom are current NDX shareholders, is
terminated in accordance with its terms.
Descriptions
of the terms of the Purchase Agreement were included in Item 1.01 of the Current Report on Form 8-K filed by the Company on September
21, 2018, and to the extent required by Item 1.02 of Form 8-K, such descriptions are incorporated by reference in this Item 1.02
pursuant to General Instruction B.3 of Form 8-K.
Item
2.04. Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet
Arrangement.
As
a result of the termination of the Merger Agreement, the Company became subject, pursuant to the Credit Agreement (the “Credit
Agreement”), dated September 18, 2018, between the Company and NDX, to an Event of Default (as defined in the Credit Agreement).
Consequently, in accordance with the Credit Agreement, the full amount of the $1.5 million advance previously paid to the Company
in connection with the signing of the Merger Agreement, plus interest thereon, became due and payable, and the interest rate under
the Credit Agreement was increased to the lesser of 21% per annum and the maximum rate permitted by applicable law.
Pursuant
to subordination agreements entered into in connection with the Credit Agreement on September 18, 2018, NDX’s ability to
be repaid under the Credit Agreement is subject to subordination to the Company’s senior secured lenders. The Company is
party to two senior loan agreements — the Amended and Restated Loan and Security Agreement among the Company, certain of
its wholly-owned subsidiaries and Silicon Valley Bank (“SVB””), dated March 22, 2017, as amended, and the Loan
and Security Agreement among the Company, certain of its wholly-owned subsidiaries and Partners for Growth IV, L.P. (“PfG”),
dated March 22, 2017, as amended.
The
Company’s default in paying the amounts due under the Credit Agreement may also result in a default under the obligations
to SVB and PfG. The Company is currently in default under certain covenants in favor of SVB and PfG, including an obligation to
raise bridge financing by November 30, and is in the process of negotiating a forbearance agreement with its lenders.
As
a result of the Event of Default under the Credit Agreement described above, NDX has the right to convert all, but not less than
all, of the outstanding balance under the Credit Agreement into shares of Company common stock at a conversion price of $0.606
per share.
Item
8.01. Other Events.
In
light of the termination of the Merger Agreement, the Company will pursue alternative strategic or financial transactions with
the assistance of Raymond James & Associates, Inc. The Company had previously retained Raymond James. as a financial advisor
to assist the Company in its evaluation of a broad range of financial and strategic alternatives to enhance shareholder value,
including additional capital raising transactions, the acquisition of another company or complementary assets or the potential
sale or merger of the Company, or another type of strategic partnership.
In
connection with the termination of the Merger Agreement, the Company issued a press release on December 17, 2018, a copy of which
is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
Forward-Looking
Statements
This
report, including Exhibit 99.1, contains forward-looking statements within the meaning of the federal securities laws. Forward-looking
statements typically are identified by use of terms such as “may,” “will,” “should,” “plan,”
“expect,” “anticipate,” “estimate” and similar words, and the opposites of such words, although
some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks and uncertainties
that exist in the Company’s operations and business environment, which may be beyond the Company’s control, and which
may cause actual results, performance or achievements to be materially different from future results, performance or achievements
expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements
that could be forward- looking statements. The risks and uncertainties referred to above include, but are not limited to, risks
detailed from time to time in the Company’s filings with the Securities and Exchange Commission, including its Annual Report
on Form 10-K for the year ended December 31, 2017 and quarterly reports on Form 10-Q for the quarters ended March 31, 2018, June
30, 2018 and September 30, 2018. These risks could cause actual results to differ materially from those expressed in any forward-
looking statements made by, or on behalf of, the Company. Forward-looking statements represent the judgment of management of the
Company regarding future events. Although the Company believes that the expectations reflected in such forward-looking statements
are reasonable at the time that they are made, the Company can give no assurance that such expectations will prove to be correct.
Unless otherwise required by applicable law, the Company assumes no obligation to update any forward-looking statements, and expressly
disclaims any obligation to do so, whether as a result of new information, future events or otherwise.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
The
following exhibits are furnished as part of this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Cancer
Genetics, Inc.
|
|
|
|
Date:
December 17, 2018
|
|
/s/
John. A Roberts
|
|
Name:
|
John
A. Roberts
|
|
Title:
|
Chief
Executive Officer
|
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2023 to Aug 2024